XOMA (NASDAQ:XOMA) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright dropped their price target on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

XOMA Stock Performance

NASDAQ XOMA opened at $27.10 on Tuesday. The stock has a fifty day simple moving average of $26.91 and a 200-day simple moving average of $27.97. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market cap of $319.24 million, a PE ratio of -7.79 and a beta of 0.90. XOMA has a twelve month low of $19.50 and a twelve month high of $35.00.

Insider Activity at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in XOMA by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock worth $607,000 after buying an additional 1,276 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of XOMA in the fourth quarter worth $206,000. New York State Common Retirement Fund increased its position in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares during the period. Rhumbline Advisers raised its stake in shares of XOMA by 18.1% in the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares in the last quarter. Finally, Barclays PLC boosted its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.